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Objective: Weight-loss is a near societal obsession and many diet programs use signif-
icant calorie restriction including fasting/short term starvation to generate rapid effects.
Fasting is also a well-recognized cause of immunosuppression especially within the innate
immune system. In this study, we sought to determine if the IL-1 arm of the neuroimmune
system was down-regulated by a 24 h fast and how fasting might generate this effect.
Design: Mice were allowed ad libitum access to food or had food withheld for 24 h. Expres-
sion of the endogenous IL-1 antagonists, IL-1 receptor type 2 (IL-1R2), and IL-1 receptor
antagonist (IL-1RA) was determined as were sickness behaviors before and after IL-1β
administration.
Results: Fasting markedly increased gene expression of IL-1R2 (83-fold in adipose tissue,
9.5-fold in liver) and IL-1RA (68-fold in liver). Fasted mice were protected from IL-1β-induced
weight-loss, hypoglycemia, loss of locomotor, and social anxiety. These protections were
coupled to a large positive interaction of fasting and IL-1β on IL-1R2 gene expression in adi-
pose tissue and liver (2.6- and 1.6-fold, respectively). Fasting not only increased IL-1RA and
IL-1R2 protein 2.5- and 3.2-fold, respectively, in liver but also increased IL-1R2 1.8-fold in adi-
pose tissue. Fasting, in turn, triggered a 2.4-fold increase in plasma free-fatty acids (FFAs)
and a 2.1-fold increase in plasma corticosterone. Inhibition, of glucocorticoid action with
mifepristone did not impact fasting-dependent IL-1R2 or IL-1RA gene expression. Adminis-
tration of the FFA, palmitate, to mice increased liver IL-1R2 and IL-1RA gene expression by
14- and 11-fold, respectively.
Conclusion:These findings indicate that fasting augments expression of endogenous IL-1
antagonists inducing IL-1 resistance. Fasting-induced increases in plasma FFAs appears to
be a signal that drives immunosuppression during fasting/short term starvation.
Keywords: fasting, starvation, IL-1, IL-1 receptor type II, IL-1R2, free-fatty acids, non-esterified fatty acids
INTRODUCTION
Within the last 20 years, the zeitgeist of body weight has become
a physiological metric that has permeated the culturally psyche
of nearly all industrialized nations. Therefore, weight-loss has
become a near societal obsession (1). Many popular diet pro-
grams initially use significant calorie restriction (CR) to facilitate
relatively rapid weight-loss (2) including the recent trend of detox
and/or cleansing diets, which may incorporate water only fast-
ing for up to 1 week. In a broad context, however, fasting is a
critical element of many religious and cultural practices (3, 4)
Abbreviations: BSA, bovine serum albumin; CR, calorie restriction; DHA, docosa-
hexaenoic acid; FFAs, free-fatty acids; IF, intermittent fasting; IP, intraperitoneal;
IL-1R2, IL-1 receptor type 2; IL-1RA, IL-1 receptor antagonist; IL-1RAcP, IL-1
receptor accessory protein; KO, knockout; LPS, lipopolysaccharide; PBS, phos-
phate buffered saline; qPCR, quantitative polymerase chain reaction; RT, room
temperature; SC, subcutaneous; WT, wild type.
and is recommended as therapy for a variety of ailments by
practitioners of alternative and complementary medicine (5–7).
Clinically, dietary regimens that incorporate intermittent fast-
ing (IF) have gained significant popular attention with human
studies showing a potential to reduce heart disease and dia-
betes (8) and to improve mood (7). Since fasting regimens
appear to benefit cognitive function in aging mice (9) and in
the 3xTgAD mouse model of Alzheimer’s disease (10), interest
in CR and IF as a way to ward off human cognitive aging has also
emerged (11).
While overeating and obesity are associated with a variety of
maladies including type 2 diabetes (T2D), heart disease, stroke
(12), cancer (13), Alzheimer’s disease (14), anxiety/mood dis-
orders (15), and cognitive impairment (11), how overnutrition
contributes is not entirely clear. Emerging evidence indicates that
oxidative and metabolic stress in conjunction with dyslipidemia
and excess glucose stimulates the unfolded protein response (16)
www.frontiersin.org July 2014 | Volume 5 | Article 315 | 1
Joesting et al. Fasting induces up-regulation of IL-1R2 and IL-1RA
and activates the NLRP3 inflammasome (17). Thus, IL-1-mediated
inflammation is a key consequence of overnutrition, whether
indirectly provoked by cellular injury (16) or directly triggered
by excess nutrients acting as danger signals (18). Overnutrition-
associated IL-1 is implicated in pancreatic beta cell loss in T2D,
atherogenesis in heart disease and stroke, and neurodegeneration
in Alzheimer’s disease but, in general, IL-1 is a critical effector of
sickness symptoms that include loss of appetite, locomotion, and
social/environmental engagement (19). Thus, ameliorations that
inhibit IL-1 bioaction may positively impact health in those with
a variety of aliments including neuropsychiatric disease (20, 21).
We recently demonstrated that mice fasted for 24 h have
reduced gene expression of brain IL-1α (22), indicating that acute
caloric restriction may be a physiological way to negatively regulate
IL-1 bioaction. Although starvation appears detrimental to immu-
nity, as evidenced by lipopolysaccharide (LPS)-induced death in
bees and mice (23, 24), fasting appears to mitigate LPS-induced
sickness symptoms in rats (25). In addition, fasting offers protec-
tion from ischemic (26) and hypoxic injuries (27), which we and
others have shown are mediated in large part by IL-1 (28). There-
fore, we examined if the physical and perceived salutary effects of
fasting are due to IL-1 counter-regulation in both the systemic and
neuroimmune systems.
MATERIALS AND METHODS
MATERIALS
All reagents and chemicals were purchased from Sigma-Aldrich
(St Louis, MO, USA) except as noted. All primers were purchased
from Applied Biosystems (Foster City, CA, USA).
ANIMALS
Procedures were conducted on protocols approved by the Univer-
sity of Illinois Institutional Animal Care and Use Committee. IL-1
receptor 1 knock out (KO), toll-like receptor (TLR-4) KO, IL-4
KO, and C57BL/6J [wild type (WT)] mice were purchased from
Jackson Laboratory (Bar Harbor, ME, USA) and bred in-house.
All KO mice were on a C57BL/6 background. Mice were group
housed (×8 cage) in standard shoebox cages (length 46.9 cm;
width 25.4 cm; height 12.5 cm) and allowed water and Harlan
chow (Indianapolis, IN, USA) ad libitum except where otherwise
noted. Housing temperature (72°F) and humidity (45–55%) were
controlled as was a 12/12 h reversed dark–light cycle (light= 2200–
1000 h). After shipping, mice were allowed at least 1 week to adjust
to the above conditions prior to experimental pre-conditioning.
Mice were handled/scruffed for 1 week prior to behavioral test-
ing and biomarker determinations. Animals were sacrificed using
CO2 except for those in which corticosterone was measured, which
were sacrificed using ketamine/xylazine. Different cohorts of mice
were used for behavioral testing and biomarker studies. The total
number of mice utilized was 430.
FASTING AND MOUSE WEIGHT
As we have described (22), 2 days prior to fasting, mice were singly
housed. Fasting was initiated by placing mice in a new cage without
food but with ad libitum water. Mice were fasted for 24 h starting at
09:00 h. Immediately after the 24 h fasting, behavioral testing, bio-
marker studies, and/or injection studies were performed. Conse-
quently, all studies occurred during the dark (active) cycle. Mouse
weight was recorded immediately before and immediately after
fasting using an Ohaus Adventurer Pro digital scale (Parsippany,
NJ, USA).
INJECTABLES
Millipore recombinant mouse IL-1β (Billerica,MA,USA) in 100µl
of sterile Cellgro PBS (Manassas, VA, USA) (vehicle) was adminis-
tered intraperitoneally (IP) at a dose of 0.9µg/mouse immediately
after fasting. Mifepristone in BioUltra 400 polyethylene glycol
(PEG) (vehicle) (PEG) was administered subcutaneously (SC) at
a dose of 25 mg/kg immediately prior to fasting. As previously
described (29), palmitate in 50 mL of castor oil (vehicle) was
administered IP at a dose of 30µmol.
QUANTITATIVE PCR
As we have described (30), animals were perfused with 30 mL
of ice cold PBS and RNA isolated from homogenized tissues
using Qiagen RNeasy Lipid Tissue Mini Kits (Valencia, CA,
USA). RNA was reverse transcribed using the Applied Biosystems
High-Capacity cDNA Reverse Transcription Kit. The TaqMan
Gene Expression primers used were: IL-1α (Mm99999060_m1),
IL-1β (Mm99999061_mH), IL-1R1 (Mm00434237_m1), IL-1RA
(Mm01337566_m1), and IL-1R2 (Mm00439622_m1). Quantita-
tive PCR (qPCR) was performed on an Applied Biosystems 7900
HT Fast Real-Time PCR System using Applied Biosystems Taq-
Man Universal PCR Master Mix. To compare gene expression, a
parallel amplification of endogenous RPS3 (Mm00656272_m1)
was performed. Reactions with no reverse transcription and no
template were included as negative controls. Relative quantitative
evaluation of target gene to RPS3 was performed by comparing
∆C ts, where C t is the threshold concentration.
LOCOMOTION
Spontaneous locomotor activity was measured as we have previ-
ously described (22, 31). At the times indicated, mice were video
recorded in their home cage for 5 min under red light using a
using a Sony Night Shot capable video camera (Minato-ku,Tokyo).
Distance moved was quantified using Noldus Information Tech-
nology EthoVision XT 7 automated tracking software (Leesburg,
VA, USA).
SOCIAL BEHAVIOR
Social exploration of a novel juvenile was measured as we have
previously described (31). In brief, a 4-week-old novel, conspecific
male juvenile (challenge) mouse enclosed in a 3′′× 3′′× 3′′ wire
mesh cage was placed in the home cage of the adult (test) mouse for
5 min. Test mouse-initiated exploratory behavior of the challenge
mouse enclosure was video recorded under red light using a Sony
Night Shot capable video camera. Time spent exploring the chal-
lenge mouse [nose within a 2 cm region of interest (ROI) drawn
around the caged juvenile] was quantified using Noldus Informa-
tion Technology EthoVision XT 7 automated tracking software
(Leesburg, VA, USA).
BLOOD GLUCOSE
Mouse tail blood glucose was determined in duplicate using
an Abbott Laboratories AlphaTRAK Blood Glucose Monitoring
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System (North Chicago, IL, USA) by methods we have previously
described (31).
SERUM, LIVER, AND ADIPOSE IL-1R2 AND IL-1RA
Serum and tissue IL-1R2 was measured using a Millipore Milliplex
MAP kit (Billerica, MA, USA) following manufactures instruc-
tions. Bead-based fluorescent reporter signal was detected on a
Luminex 100 System, where the minimum detectable concentra-
tion of IL-1R2 is 4.0 pg/mL (Austin, TX, USA). Serum and tissue
IL-1RA was measured colorimetrically. Serum (50µL) was mea-
sured by ELISA using the R&D Mouse IL-1RA/IL-1F3 conjugate
kit, where the minimum detectable concentration ranges from 4 to
13 pg/mL (Minneapolis, MN, USA). Liver and adipose IL-1R2 and
IL-1RA were measured from freeze-fractured tissues by methods
we have previously described (28). In brief, PBS perfused liver and
perigonadal adipose tissue was immediately frozen by liquid nitro-
gen in a freeze fracture buffer containing 10% glycerol, 50 mM
NaCl, 1 mM EDTA, 50 mM HEPES (pH 7.4) plus a 1:200 dilu-
tion of Millipore protease inhibitor cocktail (Billerica, MA, USA).
The fractured tissues were homogenized using the TissueLyser II
(Qiagen, Valencia, CA, USA) at a rotational frequency of 30/s for
2 min. Lysates were clarified at 16,000× g for 15 min at 4°C and
the supernatant protein concentrations determined using the Bio-
Rad DC Protein Assay (Hercules, CA, USA). IL-1R2 and IL-1RA
were determined in 25 and 50µL of supernatant, respectively, as
in serum. Liver IL-1R2 and IL-1RA was expressed as picogram of
IL-1R2 per nanogram of supernatant protein.
PLASMA CORTICOSTERONE, FREE-FATTY ACIDS (FFAs), AND LEPTIN
Mice were sacrificed immediately after the 24 h fast. Corticosterone
was measured colorimetrically using the Abcam corticosterone
ELISA kit (Cambridge, MA, USA) in 5µL plasma. Free-fatty acids
(FFAs) were measured colorimetrically in 10µL of plasma using
the Randox NEFA Assay (Antrim, Ireland) and a Beckman-Coulter
AU680 (Brea, CA, USA) following manufactures instructions.
Leptin was measured colorimetrically using the R&D Systems
leptin ELISA kit (Minneapolis, MN, USA).
STATISTICS
Individual behavioral experiments were performed on separate
cohorts of mice. Biochemical/qPCR experiments were performed
on cohorts of mice not subjected to behavioral testing. All data
are presented as mean± SEM. Data were analyzed using Sigma
Plot 11.2 (Systat Software, Chicago, IL, USA). To test for statisti-
cal differences, one-way and two-way ANOVAs were used with or
without repeated measurements where relevant. Tukey’s test was
used for post hoc pair-wise multiple comparison procedures. Pear-
son product moment correlation was used to compute correlation
coefficient. Where indicated, raw data were transformed to attain
normality or equal variance. All statistical analysis included test-
ing for time point× treatment interactions. Statistical significance
was denoted at P < 0.05.
RESULTS
FASTING UP-REGULATES IL-1R2 GENE EXPRESSION IN ADIPOSE
TISSUE AND LIVER
Table 1 demonstrates the gene expression of IL-1α, IL-1β,
IL-1R1, IL-1RA, and IL-1R2 in brain regions (hypothalamus,
hippocampus, and cortex), adipose tissue, and liver after a 24 h
fast. The largest fold changes between the fed and fasted state were
seen in the up-regulation of IL-1RA message in liver and in IL-1R2
message in adipose tissue and liver.
UP-REGULATION OF IL-1R2 GENE EXPRESSION IN LIVER AND ADIPOSE
TISSUE CORRELATES WITH LOSS OF BODY WEIGHT
Figures 1A,C show that IL-1R2 gene expression was up-regulated
26-fold in liver after a 24 h fast (∆CT fed vs. fasted, 1.082± 0.095
vs. 27.975± 13.853, P < 0.001) and that the correlation between
% weight-loss and gene expression was −0.530 (P = 0.002).
Figures 1B,D demonstrate that IL-1R2 gene expression was
Table 1 | Impact of fasting on IL-1α, IL-1β, IL-1R1, IL-1RA, and IL-1R2 gene expression in brain, adipose tissue, and liver.
Tissue State Gene
IL-1α IL-1β IL-1R1 IL-1RA IL-1R2
Hypothalamus Fed 1.000 (0.06, 0.06) 1.000 (0.17, 0.15) 1.000 (0.10, 0.09) 1.000 (0.33, 0.25) 1.000 (0.13, 0.12)
Fasted 0.567* (0.03, 0.03) 0.487* (0.05, 0.05) 1.484* (0.12, 0.11) 0.920 (0.25, 0.20) 1.104 (0.05, 0.05)
Hippocampus Fed 1.000 (0.05, 0.05) 1.000 (0.09, 0.08) 1.000 (0.20, 0.17) 1.000 (0.11, 0.10) 1.000 (0.10, 0.09)
Fasted 0.565* (0.03, 0.03) 0.791 (0.06, 0.05) 1.600* (0.18, 0.10) 1.600* (0.33, 0.27) 0.880 (0.09, 0.08)
Cortex Fed 1.000 (0.11, 0.10) 1.000 (0.12, 0.11) 1.000 (0.03, 0.03) 1.000 (0.14, 0.13) 1.000 (0.04, 0.04)
Fasted 0.496* (0.03, 0.02) 0.9018 (0.11, 0.010) 1.319* (0.06, 0.05) 1.066 (0.12, 0.10) 1.061 (0.06, 0.06)
Adipose Fed 1.000 (0.58, 0.37) 1.000 (0.36, 0.27) 1.000 (0.11, 0.10) 1.000 (0.34, 0.25) 1.000 (0.25, 0.02)
Fasted 0.295 (0.05, 0.04) 0.167* (0.04, 0.03) 2.334* (0.36, 0.31) 0.774 (0.16, 0.13) 83.424* (79.04, 40.59)
Liver Fed 1.000 (0.14, 0.12) 1.000 (0.13, 0.11) 1.000 (0.13, 0.11) 1.000 (1.56, 0.64) 1.000 (0.15, 0.13)
Fasted 0.857 (0.03, 0.03) 0.979 (0.34, 0.25) 3.130* (0.95, 0.70) 68.482* (38.6, 24.7) 9.467* (19.35, 6.36)
Results are expressed as relative fold change in mRNA (∆mRNA), means (SEM upper, SEM lower); n=4–9. *P<0.05, significant (one-way ANOVA). Adipose IL-1R2
and liver IL-1R2 transformed to RANK for equal variances.
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FIGURE 1 | Up-regulation of IL-1R2 gene expression in liver and adipose
tissue correlates with loss of body weight. Mice were fed or fasted for
24 h. Box plots are representative of the summated relative fold changes in
mRNA transformed to log; the box outlines the lower first quartile and upper
third quartile, the vertical bars represent the largest/smallest non-outlier
observation, the thick horizontal line represents the mean of the relative fold
change values, and the thin horizontal line is the median. Black circles
represent outliers. (A) Liver IL-1R2 gene expression is summarized and
expressed as log [average relative fold change (∆mRNA)] for fed (n= 29) and
fasted groups (n= 31) *P <0.001. (B) Adipose tissue IL-1R2 gene expression
is summarized and expressed as log [average relative fold change (∆mRNA)]
for fed (n=29) and fasted groups (n=30) *P <0.001. (C) Percent weight lost
per mouse was correlated to delta CT value for IL-1R2 in the liver, significant
correlation was observed P = 0.002, n= 31. (D) Percent weight lost per
mouse was correlated to delta CT value for IL-1R2 in the adipose tissue,
significant correlation was observed P < 0.001, n= 30.
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up-regulated 62-fold in adipose tissue after a 24 h fast (∆CT fed vs.
fasted, 1.118± 0.089 vs. 69.577± 21.829, P < 0.001) and that the
correlation between % weight-loss and gene expression of IL-1R2
was −0.601 (P < 0.001). Although IL-1RA gene expression was
up-regulated in liver by 28-fold (∆CT fed vs. fasted, 1.219± 0.140
vs. 33.792± 6.292, P < 0.001) there was no % weight-loss corre-
lation [R2=−0.306 (P = 0.094)] (data not shown). On average,
fasting induced a 12.6% loss in body weight (fed 23.63± 0.46 g vs.
fasted 20.98± 0.46 g P < 0.001).
FASTED MICE ARE RESISTANT TO IL-1β
Figures 2A,B show that fasted mice are resistant to
IL-1β-induced weight-loss and hypoglycemia [(fed saline
−0.400± 0.204 g vs. fasted saline −0.300± 0.108 g vs. fed
IL-1β −1.280± 0.180 g vs. fasted IL-1β −0.240± 0.067 g);
main effects of treatment (P = 0.016) and state (P = 0.002),
treatment–state interaction (P < 0.007) and (fed saline−12.000±
18.898 mg/dL vs. fasted saline −5.750± 18.368 mg/dL vs. fed IL-
1β −111.200± 14.900 mg/dL vs. fasted IL-1β −11.400± 7.619
mg/dL); main effects of treatment (P = 0.004) and state
(P = 0.003) and treatment–state interaction (P < 0.007)], respec-
tively. Figures 2C,D demonstrate that fasted mice are resistant
to the IL-1β-induced sickness behaviors of reduced locomotion
and social withdrawal (fed saline 1213.374± 36.764 cm vs. fasted
saline 1012.946± 115.244 cm vs. fed IL-1β 131.176± 74.121 cm
vs. fasted IL-1β 731.617± 110.055 cm); main effects of treat-
ment (P < 0.001) and state (P = 0.046), treatment–state inter-
action (P < 0.001), and fed saline 123.5± 16.5 s vs. fasted
saline 172.4± 9.7 s vs. fed IL-1β 62.7± 13.1 s vs. fasted IL-1β
112.9± 22.3 s; main effects of treatment (P < 0.001) and state
(P = 0.004), no treatment–state interaction (P = 0.980)]. Table 2
shows the impact of a 24 h fast on IL-1β-induced changes in gene
expression of IL-1α, IL-1β, IL-1R1, IL-1RA, and IL-1R2 in brain
regions (hypothalamus, hippocampus, and cortex), adipose tissue,
and liver. The largest IL-1β-dependent fold changes seen were in
the up-regulation of IL-1RA and IL-1R2 message in adipose tissue
and liver. In adipose tissue, fasting suppressed IL-1β-dependent
expression of IL-1R1 and IL-1RA message but enhanced expres-
sion of IL-1R2 message. In liver, fasting increased IL-1β-dependent
expression of IL-1R2 message.
FIGURE 2 | Fasted mice are resistant to IL-1β. Mice were fed or fasted for
24 h. prior to IP IL-1β or vehicle (Saline) administration. (A) Mice were
weighed 2 h after IL-1β administration and compared to their weight just
prior to IL-1β administration. Results are expressed as weight change in
grams (g), means (±SEM); n=4–5. Bars without a common superscript are
different (*P <0.05). (B) Blood glucose was measured 2 h after IL-1β
administration and compared to blood glucose just prior to IL-1β
administration. Results are expressed as change in blood glucose
(microgram/deciliter), means (±SEM); n=4–5. Bars without a common
superscript are different (P <0.05). (C) Spontaneous locomotor activity was
measure 2 h after IL-1β administration. Results are expressed as total
distance traveled in centimeters (cm), means (±SEM); n=4. Bars without a
common superscript are different (*P <0.05). (D) Social exploration was
measured 2 h after IL-1 administration. Results are expressed as total time
of exploration (sec), means (±SEM); n=8. Bars without a common
superscript are different (P <0.05).
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Table 2 | Impact of fasting on IL-1α, IL-1β, IL-1R1, IL-1RA, and IL-1R2 gene expression in brain, adipose tissue, and liver of mice treated with IL-1β.
Tissue Rx State Gene
IL-1α IL-1β IL-1R1 IL-1RA IL-1R2
Hypothalamus Saline Fed 1.00a (0.18, 0.15) 1.00a (0.41, 0.29) 1.00a,b (0.21, 0.17) 1.00a (0.44, 0.30) 1.00a (0.12, 0.11)
Fasted 0.71b (0.04, 0.03) 0.42b (0.07, 0.06) 0.75a (0.04, 0.04) 0.46b (0.04, 0.03) 1.27a (0.04, 0.04)
IL-1β Fed 13.5c (0.61, 0.59) 72.80c (14.9, 12.4) 1.51a,b (0.30, 0.26) 52.10c (2.89, 2.74) 1.82b (0.19, 0.17)
Fasted 10.4c (1.22, 1.08) 69.31c (9.66, 8.48) 1.19b (0.09, 0.08) 34.20d (3.06, 2.81) 1.87b (0.23, 0.20)
Hippocampus Saline Fed 1.00a (0.06, 0.06) 1.00a (0.13, 0.11) 1.00a (0.14, 0.13) 1.00a (0.41, 0.29) 1.00a (0.17, 0.15)
Fasted 0.74a (0.06, 0.05) 0.97a (0.04, 0.04) 1.21a,b (0.05, 0.05) 0.87a (0.26, 0.20) 1.15a (0.10, 0.09)
IL-1β Fed 7.64b (0.56, 0.52) 11.30b (1.35, 1.21) 1.64b (0.08, 0.08) 49.60b (8.32, 7.12) 1.81b (0.25, 0.22)
Fasted 7.67b (1.57, 1.31) 12.60b (2.13, 1.83) 1.54a,b (0.07, 0.07) 31.40b (5.17, 4.44) 2.29b (0.31, 0.27)
Cortex Saline Fed 1.00a (0.07, 0.07) 1.00a (0.05, 0.05) 1.00a (0.11, 0.10) 1.00a (0.06, 0.06) 1.00a (0.03, 0.03)
Fasted 0.58b (0.07, 0.06) 0.85a (0.11, 0.09) 1.13a (0.12, 0.08) 1.11a (0.17, 0.15) 1.27b (0.07, 0.07)
IL-1β Fed 8.91c (0.96, 0.86) 11.10b (1.71, 1.48) 2.16b (0.19, 0.18) 23.60b (3.14, 2.76) 1.58c (0.12, 0.11)
Fasted 7.35c (1.36, 1.15) 10.40b (1.48, 1.29) 1.94b (0.16, 0.15) 16.50b (2.57, 2.23) 1.90d (0.10, 0.09)
Adipose Saline Fed 1.00a (0.16, 0.14) 1.00a (0.39, 0.28) 1.00a (0.24, 0.19) 1.00a (0.25, 0.20) 1.00a (0.38, 0.28)
Fasted 1.16a (0.83, 0.48) 0.84a (0.53, 0.32) 0.68a (0.17, 0.14) 0.62a (0.21, 0.16) 12.9b (8.59, 5.16)
IL-1β Fed 9.83b (3.31, 2.47) 27.50b (7.11, 5.65) 10.80b (0.63, 0.59) 22.70b (2.70, 2.41) 69.2c (11.0, 9.51)
Fasted 4.14b (2.38, 1.51) 24.60b (6.31, 5.02) 2.97c (0.47, 0.40) 12.35c (1.58, 1.40) 177.9d (39.4, 32.2)
Liver Saline Fed 1.00a (0.10, 0.09) 1.00a (0.19, 0.16) 1.00a (0.06, 0.06) 1.00a (0.21, 0.17) 1.00a (0.19, 0.16)
Fasted 0.98a (0.06, 0.06) 1.19a (0.28, 0.23) 1.23a (0.38, 0.29) 9.60b (1.00, 0.91) 4.22b (2.31, 1.49)
IL-1β Fed 1.24a (0.19, 0.17) 4.48b (0.62, 0.54) 7.16b (0.44, 0.41) 463.0c (23.7, 22.5) 124.5c (5.61, 5.37)
Fasted 1.13a (0.15, 0.14) 4.06b (0.84, 0.70) 9.96b (2.23, 1.82) 450.5c (54.5, 48.6) 200.9d (19.0, 17.4)
Results are expressed as relative fold change in mRNA (∆mRNA), means (SEM upper, SEM lower); n=8.
Values without a common superscript are different (*P<0.05) (two-way ANOVA). Hypothalamus IL-1RA transformed to RANK for normality. Liver IL-1R2 transformed
to RANK for equal variance.
Table 3 | Effect of fasting on IL-1R2 and IL-1RA protein levels.
Tissue IL-1R2 IL-1RA
Fed Fasted Fed Fasted
Liver 8,475±1,837 27,140*±8,993 29,054±3,580 71,722*±11,176
Adipose 41,375±4,681 73,788*±8,716 630±157 442±277
Serum 11,112±393 10,647±350 662±113 694±96
Results are expressed as (liver picogram IL-1R2 or IL-1RA/nanogram total protein, fat picogram IL-1R2 or IL-1RA/nanogram total and serum picogram IL-1R2 or
IL-1RA/milliliter) means (±SEM); liver IL-1R2 n=7–8; liver IL-1RA n=13–16; adipose IL-1R2 n=8; adipose IL-1RA n=8; serum IL-1R2 n=8; serum IL-1RA n=8:
*P<0.05, significant (one-way ANOVA). Liver IL-1R2 protein transformed to log(abs) for normality. Liver IL-1RA protein transformed to log(abs) for equal variance.
IL-1RA, IL-1R2, FFAs, AND CORTICOSTERONE ARE INCREASED IN
FASTED MICE
Table 3 demonstrates that IL-1RA and IL-1R2 are increased by
fasting 2.47- and 3.2-fold, respectively, in liver. Fasting increased
IL-1R2 in fat 1.78-fold. Fasting did not impact IL-1RA or IL-1R2
in serum. Figure 3A shows that fasting more than doubled plasma
FFAs [fed 0.927± 0.104 mmol/L vs. fasted 2.207± 0.161 mmol/L;
main effect of state (P < 0.001)]. In turn, fasting decreased
serum leptin [fed 15,260± 1496 pg/mL vs. 9311± 1088 pg/mL
(P = 0.006)] (data not shown). Fasting also increased plasma
corticosterone (Figure 3B) by 2.05-fold [fed 368± 29 ng/mL vs.
fasted 755± 84 ng/mL; main effect of state (P = 0.004)]. Figure 3C
shows that plasma corticosterone correlated positively with per-
cent mouse body weight lost during fasting (R2= 0.9; P = 0.005).
Figures 3D,E demonstrate that inhibiting glucocorticoid signaling
with the glucocorticoid receptor antagonist mifepristone did not
prevent up-regulation of IL-1R2 or IL-1RA gene transcripts in
the liver after fasting [IL-1R2-fed PEG 1.327, +0.126 −0.115
vs. fasted PEG 3.471, +0.661 −0.555 vs. fed mifepristone 1.789,
+0.299 −0.256 vs. fasted mifepristone 4.790, +0.609 −0.540;
main effects of treatment (P = 0.058) and state (P < 0.001) no
significant treatment–state interaction (P = 0.160): IL-1RA-fed
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FIGURE 3 | Free-fatty acids and corticosterone are increased in
fasted mice. Mice were fed or fasted for 24 h. (A) Plasma FFAs were
measured at 24 h and results are expressed as millimoles per liter, fed
vs. fasted, means (±SEM); n=3–4. Significant main effect
(*P <0.001). (B) Plasma corticosterone was measured at 24 h. Results
are expressed as nanogram per milliliter corticosterone, means
(±SEM); n=5–7. Significant main effect (*P <0.05). (C) Plasma
corticosterone was correlated to percent weight lost by mouse; n=5–7,
P =0.005. (D,E) Mice were treated SQ with or without mifepristone
then fed or fasted for 24 h. Gene expression of IL-1R2 and IL-1RA were
measured in the liver. IL-1R2 gene expression was expressed as relative
fold change in mRNA, means (+SEM upper, −SEM lower); n=4–6.
Bars without a common superscript are different (*P < 0.05). IL-1RA
gene expression was expressed as relative fold change in mRNA,
means (+SEM upper, −SEM lower); n=4–6. Bars without a common
superscript are different (*P < 0.05).
PEG 1.086, +0.152 −0.133 vs. fasted PEG 5.182, +1.395 −1.099
vs. fed mifepristone 1.236, +0.157 −0.140 vs. fasted mifepris-
tone 9.521,+1.587−1.260; main effects of treatment (P = 0.077)
and state (P < 0.001), no significant treatment–state interaction
(P = 0.161)]. Blood glucose was used to confirm the effectiveness
of mifepristone (fasted PEG 141 mg/dL vs. fasted mifepristone
91 mg/dL).
ADMINISTRATION OF PALMITATE INCREASES GENE EXPRESSION OF
IL-1R2 AND IL-1RA IN THE LIVER
Table 4 shows that 1 and 12 h after palmitate acid administration
gene expression of IL-1RA and IL-1R2 was increased by 11- and
14-fold, respectively, in liver. Whole animal KO of TLR-4, IL-1R1,
or IL-4, did not prevent fasting-dependent increases in IL-1R2
(liver and adipose tissue) and IL-1RA (liver), data not shown.
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Table 4 | Effect of FFA treatment on liver gene expression.
Time Treatment Gene
IL-1RA IL-1R2
1 h Vehicle 1.000a,b (0.47, 0.32) 1.000a (0.23, 0.19)
Palmitate 0.993b (0.48, 0.32) 1.594a (0.35, 0.29)
12 h Vehicle 1.702a (1.02, 0.64) 2.301b (0.95, 0.67)
Palmitate 10.773c (2.41, 1.97) 14.242c (2.06, 1.80)
Results are expressed as relative fold change in mRNA (∆mRNA) vs. 1 h vehi-
cle treatment, means (SEM upper, SEM lower); n=6. Values with different
superscripts are significantly different (P<0.05).
DISCUSSION
Fasting and/or acute starvation causes resistance to LPS-induced
sickness behaviors (25, 32, 33) of which IL-1 is a critical effector
molecule (34). The importance of IL-1 to LPS-induced sickness
symptoms is demonstrated by experiments in which, prophy-
laxis with IL-1RA prior to LPS administration attenuates sickness
behaviors (35). How acute caloric restriction moderates sickness,
however, is not clearly understood. Restricting caloric intake is
the most effective nutritional intervention for preventing dia-
besity in rodents, primates, and humans (36), and this intervention
appears anti-inflammatory reducing pro-inflammatory biomark-
ers in the diabetes (36) and mitigating sickness behaviors caused
by microbial-derived pathogens in rodents (32). Here, we show
that fasting up-regulates the mRNA and protein concentration
of both IL-1R2 and IL-1RA with liver being a key repository of
IL-1R2 and IL-1RA and adipose tissue being limited to IL-1R2
expression. Previous work suggests that the anti-inflammatory
effect of fasting is, in part, related to leptin (33). While leptin
may act as a pro-inflammatory (37), its exact role in inflamma-
tion is murky (38). As expected, we see a significant decrease
in circulating leptin due to our fast. This finding also supports
the lack of an IL-1RA increase in adipose tissue. As we have
shown, leptin drives IL-1RA production in mouse adipose tis-
sue (39, 40). This leptin-generated IL-1RA originates from fat-
based macrophages (41) and is dependent on the long form of
the leptin receptor, leptin receptor-dependent activation of the
ERK/MAPK pathway and the binding of nuclear factor-κB/PU.1
within the IL-1RA promoter region (42). Since blood leptin is
decreased, adipose-derived IL-1RA is expected to be decreased
or unchanged, as we see. Furthermore, leptin does not appear to
directly regulate IL-1R2 gene expression because the IL-1R2 pro-
moter lacks regions impacted by transcription factors driven by
leptin (43). Unexpectedly, liver IL-1RA was up-regulated by fast-
ing, but it did not correlate with % change in body weight as did
IL-1R2, where a 15% loss of weight appears to be a threshold for
marked IL-1R2 up-regulation. Taken together, these findings sug-
gest that during starvation IL-1R2 is a biomarker of pronounced
weight loss.
Sickness behaviors are adaptive changes that occur in response
to infection (44) and are, thus, a sensitive indicator of inflam-
mation. Dramatic reductions in food intake are commonly asso-
ciated with localized and systemic illness (45–47), but sickness-
associated anorexia is attenuated if food is restricted prior to
IL-1β administration (48, 49). Acute starvation also reduces the
fever response to LPS in rats (25). Here, we show that fasting
prior to IL-1β administration not only attenuates weight loss but
also protects mice from IL-1β-induced loss of locomotor activ-
ity and social exploratory behavior. As with almost all animals,
mice socially withdraw when sick and spend less time moving
(19, 50). Whether these behaviors are a form of energy conserva-
tion or an evolutionarily helpful isolation to protect others form
the spread of disease, is not known. In that, pre-sickness energy
restriction (fasting) blunts these sickness responses allowing for
a reduction in “self-imposed” social isolation, self-preservation,
and/or energy needs to fight infection may be paramount over
protecting others. Thus, our findings support the concept that
acute caloric restriction is anti-inflammatory at least within the
IL-1-arm of the immune system. Part of IL-1-driven inflamma-
tion is the feed-forward effect of IL-1 on IL-1 expression. Here,
we show that brain and adipose tissue are especially sensitive to
IL-1β-dependent up-regulation of IL-1α and IL-1β. Liver, in con-
trast, is less affected by IL-1βwith IL-1α showing no up-regulation.
Interestingly, fasting alone had little impact on IL-1-driven IL-1α
or IL-1β message. In terms of IL-1R1, fasting only impacts its
gene expression in adipose tissue. Fasting, however, dramatically
influences IL-1-driven changes in endogenous antagonist expres-
sion. Not only were large fold changes in IL-1RA and IL-1R2
message seen in brain, liver, and adipose tissue due to exoge-
nous IL-1β administration, but under these conditions fasting
further augmented IL-1R2 expression in cortex, adipose tissue,
and liver. Unexpectedly, fasting blunts IL-1RA gene expression in
hypothalamus and adipose tissue. However, because of the impor-
tance of IL-1RA to inhibit both IL-1α and IL-1β, some argue
that IL-1RA is a biomarker of inflammation severity (51). Given
our results, we favor IL-1RA as a somewhat non-specific anti-
inflammatory that is critical to dampening runaway inflammation
best exampled by cytokine storm seen in some cases of very severe
influenza.
Since fasting does not increase serum IL-1RA or IL-1R2, a key
question is how might CR-dependent up-regulation of endoge-
nous IL-1 antagonists in tissues create IL-1 resistance. Unlike
IL-1RA, which exists in a single form, IL-1R2 exists in two forms
one which is membrane bound and one which is soluble (sIL-1R2)
(43). As with IL-1RA, IL-1R2 serves as a negative regulator of IL-
1 signaling, but instead of blocking the IL-1R1 receptor as does
IL-1RA, IL-1R2 competes with the IL-1R1 for IL-1. In addition, IL-
1R2 can complex with IL-1 receptor accessory protein (IL-1RAP)
to ineffectualize IL-1R1 signaling (43). Intracellular sIL-1R2 has
long been known to sequester pro-IL-1β, where it interferes with
caspase-1-dependent IL-1β maturation (52). More recently, sIL-
1R2 has been shown to complex with the pro-IL-1α inhibiting its
enzymatic maturation by calpain (53). Therefore, increased intra-
cellular expression of IL-1R2 blocks maturation of both IL-1α and
IL-1β. Such a mechanism would be very important to regulate sick-
ness behaviors because the communication of cytokine-mediated
sickness signals from the periphery to the brain is reliant, in
part, on de novo synthesis of IL-1 (54). This is evidenced in
rodents, which have undergone sub-diaphragmatic vagotomy hav-
ing reduced sickness behaviors and IL-1βmRNA in the brain after
IP IL-1β administration (55, 56). Recently, the liver–brain axis has
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gained importance due to the debilitating sickness systems asso-
ciated with liver inflammation (54). In that, IF has emerged as
a tool in thwarting overnutrition-dependent inflammation (57),
increased intracellular sIL-1R2 may be a mechanism by which fast-
ing dampens both liver- and adipose tissue-based inflammation
while inhibiting the ability of these tissues to communicate with
vagal afferents through mature/secreted IL-1.
Fasting, via activation of the sympatho-adrenomedullary sys-
tem, generates a metabolic profile that favors utilization of long-
chain fatty acids (58). Since glucocorticoids are one of the best
described inducers of IL-1R2 expression (43), we used the steroid
receptor blocker mifepristone (59) to dampen fasting-induced IL-
1R2 and IL-1RA expression. While mifepristone prevented fasting-
dependent hyperglycemia (data not shown), it did not reduce gene
expression of IL-1R2 or IL-1RA. Due to recent work showing that
FFAs can induce sickness-like symptoms in a TLR4-, IL-1R1-,
and MyD88-independent fashion (29), we administered palmi-
tate to determine if IL-1R2 and IL-1RA gene expression in liver is
induced. The effect was small 1 h after palmitate administration
but robust after 12 h. Since fasting increases IL-1R2 and IL-1RA
gene expression in TLR4 KO mice, FFAs stimulating TLRs is not a
likely mechanism by which fasting augments anti-inflammation.
In addition, other physiological processes associated with FFA-
induced TLR activation (60) are not described in acute fasting such
as induction of TNF-α (61). Thus, FFAs such as palmitate may act
as anti-inflammatories via interactions with G-protein receptor
(GPR)40 also known as FFA receptor 1 (FFAR1) (62). Such a possi-
bility has been shown in vitro with docosahexaenoic acid (DHA) in
LPS-treated macrophages, where pretreatment with DHA inhibits
caspase-1 activation and IL-1β secretion via a mechanism reliant
on GPR120 and GPR40 (63). Taken together, our findings indi-
cate that increases in long-chain fatty acids during fasting may be
partially responsible for the immunosuppression-like phenotype
observed during fasting/short term starvation by inhibiting the IL-
1-arm of the immune system. More work is needed to determine
precisely how weight loss triggers up-regulation of endogenous
IL-1 antagonist.
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